Business Description
Zenas BioPharma Inc
NAICS : 541713
SIC : 2834
ISIN : US98937L1052
Total Employee Number:
167Description
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.69 | |||||
Equity-to-Asset | 0.45 | |||||
Debt-to-Equity | 0.8 | |||||
Debt-to-EBITDA | -0.66 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -12.4 | |||||
3-Year EPS without NRI Growth Rate | 7.6 | |||||
3-Year FCF Growth Rate | 4.2 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 19.75 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 126.75 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 65.39 | |||||
9-Day RSI | 62.9 | |||||
14-Day RSI | 63.36 | |||||
3-1 Month Momentum % | 43.64 | |||||
6-1 Month Momentum % | 26.97 | |||||
12-1 Month Momentum % | 87.03 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 11.94 | |||||
Quick Ratio | 11.94 | |||||
Cash Ratio | 11.73 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -11 | |||||
Shareholder Yield % | -11.43 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
FCF Margin % | -2454.8 | |||||
OCF Margin % | -2104.78 | |||||
ROE % | -163.73 | |||||
ROA % | -102.19 | |||||
ROIC % | -854.18 | |||||
3-Year ROIIC % | -383.69 | |||||
ROC (Joel Greenblatt) % | -35684.33 | |||||
ROCE % | -113.1 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 144.8 | |||||
PB Ratio | 6.03 | |||||
Price-to-Tangible-Book | 6.03 | |||||
EV-to-EBIT | -3.92 | |||||
EV-to-EBITDA | -3.92 | |||||
EV-to-Revenue | 159.7 | |||||
EV-to-Forward-Revenue | 31.94 | |||||
EV-to-FCF | -6.51 | |||||
| Price-to-Net-Current-Asset-Value | 6.36 | |||||
| Price-to-Net-Cash | 6.63 | |||||
Earnings Yield (Greenblatt) % | -25.51 | |||||
FCF Yield % | -11.99 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ZBIO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Zenas BioPharma Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 10 | ||
| EPS (TTM) ($) | -8.47 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 102.15 | ||
| 14-Day RSI | 63.36 | ||
| 14-Day ATR ($) | 1.807317 | ||
| 20-Day SMA ($) | 30.9345 | ||
| 12-1 Month Momentum % | 87.03 | ||
| 52-Week Range ($) | 13.5 - 44.6 | ||
| Shares Outstanding (Mil) | 63.13 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Zenas BioPharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Zenas BioPharma Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-12 | In 95 days | ||
| Second quarter earnings results for 2026 | 2026-08-12 | In 3 days | ||
| H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit | 2026-06-15 07:00 | 19.80 (+11.36%) | ||
| First quarter earnings results for 2026 | 2026-05-13 | 19.16 (-6.08%) | ||
| General meeting for 2026 | 2026-05-11 08:00 | 19.64 (+1.92%) | ||
| Annual report for 2025 | 2026-03-16 | 24.04 (-3.57%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-16 | 24.04 (-3.57%) | ||
| Guidance call for 2026 | 2026-02-11 13:30 | 21.48 (-4.45%) | ||
| Zenas BioPharma Phase 3 IgG4-RD Registration Trial Topline Results | 2026-01-05 08:00 | 34.50 (-4.98%) | ||
| 8th Annual Evercore Healthcare Conference | 2025-12-03 07:55 | 34.50 (-7.75%) |
Show
Entries
Zenas BioPharma Inc Frequently Asked Questions
What is Zenas BioPharma Inc(ZBIO)'s stock price today?
The current price of ZBIO is $32.43. The 52 week high of ZBIO is $44.60 and 52 week low is $13.50.
When is next earnings date of Zenas BioPharma Inc(ZBIO)?
The next earnings date of Zenas BioPharma Inc(ZBIO) is 2026-08-12 Est..
Does Zenas BioPharma Inc(ZBIO) pay dividends? If so, how much?
Zenas BioPharma Inc(ZBIO) does not pay dividend.
Guru Commentaries on NAS:ZBIO
No articles.
Press Release
Articles on Zenas BioPharma Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers